Atrys HealthXMAD:ATRY -0.97%66 Gross Margin % is 41.72% as of Dec. 2025, which is 48% below its 10-year median of 80.89. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.11 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 738 Biotechnology companies, Atrys Health ranks worse than 54.88% on this metric.
Atrys Health SA gross margin has been in long-term decline. The average rate of decline per year is -12.1%.
The historical rank and industry rank for Atrys Health's Gross Margin % or its related term are showing as below:
XMAD:ATRY'
s Gross Margin % Range Over the Past 10 Years
Min: 43.51 Med: 80.89 Max: 97.66
Current: 56.36
During the past 10 years, the highestGross Margin % of Atrys Health was 97.66%. The lowest was 43.51%. And the median was 80.89%.
XMAD:ATRY's Gross Margin % is ranked worse than 54.88% of 738
companies
in the Biotechnology industry
Industry Median: 60.94
vs XMAD:ATRY: 56.36
Atrys Health had a gross margin of 41.72% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Atrys Health was -12.10% per year.
Atrys Health (XMAD:ATRY) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Atrys Health had a gross margin of 41.72% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Atrys Health Gross Margin % Related Terms
Atrys Health Gross Margin % Historical Data
* Premium members only.
The historical data trend for Atrys Health's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Atrys Health's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Atrys Health's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Atrys Health (XMAD:ATRY) has a Gross Margin % of 41.72% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Atrys Health and its competitors. This is 48% below median its historical median of 80.89. Over the past decade, Atrys Health's Gross Margin % has ranged from 43.51 to 97.66. According to the industry distribution chart, Atrys Health ranks #405 out of 738 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Atrys Health's Gross Margin % too high?
Atrys Health's current Gross Margin % of 41.72% is 48% below median its 10-year median of 80.89. Over the past 10 years, this metric has ranged from a low of 43.51 to a high of 97.66. The Biotechnology industry median Gross Margin % is 60.94. Atrys Health's value of 41.72% is 31.5% below this industry median. Based on the distribution chart, Atrys Health ranks #405 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #405 out of 738 companies for Gross Margin %. This places Atrys Health in the lower half of its industry. The industry median Gross Margin % is 60.94. Atrys Health's value of 41.72% is 31.5% below this benchmark. Historically, Atrys Health's own Gross Margin % has ranged from 43.51 to 97.66 over the past decade. While the company's 10-year median is 80.89 vs. the industry median of 60.94, Atrys Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrys Health's current Gross Margin % of 41.72% is 31.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Atrys Health and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrys Health's current Gross Margin % is 41.72%, which is 48% below median its own 10-year median of 80.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.57 — trading 17.5% below its estimated fair value. The current Gross Margin % is 41.72%, which is 48% below median its 10-year median of 80.89 and 31.5% below the Biotechnology industry median of 60.94. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Gross Margin % is 41.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.57 is trading 17.5% below its estimated GF Value™ of €3.11.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
Gross Margin %: 41.72% (48% below median its 10-year median of 80.89)
GF Value™: €3.11 vs. price of €2.57 (17.5% below fair value)
Industry Position: 31.5% below the Biotechnology median (#405 of 738)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score
Get the complete analysis for XMAD:ATRY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
